Literature DB >> 16116207

Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2.

Arik Cooper1, Guy Tal, Ofer Lider, Yosef Shaul.   

Abstract

The hepatitis B virus (HBV) core Ag (HBcAg) serves as the structural subunit of the highly immunogenic capsid shell. HBcAg harbors a unique arginine-rich C terminus that was implicated in immune responses induced by the capsid. In this study, we examined the capacity of the HBV capsid to induce proinflammatory and regulatory cytokines in human THP-1 macrophages and the possible underlying mechanism. Full-length HBc capsids, but not HBc-144 capsids lacking the arginine-rich domain of HBcAg, efficiently bound differentiated THP-1 macrophages and strongly induced TNF-alpha, IL-6, and IL-12p40. Capsid binding to macrophages and cytokine induction were independent of the RNA associated with the arginine-rich domain. Soluble heparin and heparan sulfate but not chondroitin sulfates greatly diminished cytokine induction through inhibition of capsid binding to THP-1 macrophages. Furthermore, serine phosphorylation in the arginine-rich domain modulates capsid binding to macrophages and the cytokine response. Induction of cytokines by the capsid involved activation of NF-kappaB, ERK-1/2, and p38 MAPK and did not require endosomal acidification. Finally, NF-kappaB activation by the capsid in HEK 293 cells specifically required expression of TLR2 and was compromised by soluble heparin. Thus, cytokine induction by the HBV capsid in macrophages is facilitated by interaction of its arginine-rich domain with membrane heparan sulfate and involves signaling through TLR2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116207     DOI: 10.4049/jimmunol.175.5.3165

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

Review 1.  Regulation of B-cell responses by Toll-like receptors.

Authors:  Edward P Browne
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

2.  Interaction of the hepatitis B core antigen and the innate immune system.

Authors:  Byung O Lee; Amy Tucker; Lars Frelin; Matti Sallberg; Joyce Jones; Cory Peters; Janice Hughes; David Whitacre; Bryan Darsow; Darrell L Peterson; David R Milich
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

Review 3.  Macrophages in hepatitis B and hepatitis C virus infections.

Authors:  Mathis Heydtmann
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

4.  Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.

Authors:  Katleen Broos; Michiel E Janssens; Ine De Goeyse; Peter Vanlandschoot; Geert Leroux-Roels; Dirk Geysen; Yves Guisez
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

Review 5.  Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.

Authors:  Jieliang Chen; Zhenghong Yuan
Journal:  Virol Sin       Date:  2014-01-20       Impact factor: 4.327

Review 6.  Living in the liver: hepatic infections.

Authors:  Ulrike Protzer; Mala K Maini; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2012-02-24       Impact factor: 53.106

Review 7.  Herpesviral infection and Toll-like receptor 2.

Authors:  Ming-sheng Cai; Mei-li Li; Chun-fu Zheng
Journal:  Protein Cell       Date:  2012-08-04       Impact factor: 14.870

Review 8.  Heparanase and hepatocellular carcinoma: promoter or inhibitor?

Authors:  Shuo Dong; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

9.  Toll-like receptors as targets in chronic liver diseases.

Authors:  A Mencin; J Kluwe; R F Schwabe
Journal:  Gut       Date:  2009-05       Impact factor: 23.059

10.  Macrophage interleukin-6 and tumour necrosis factor-alpha are induced by coronavirus fixation to Toll-like receptor 2/heparan sulphate receptors but not carcinoembryonic cell adhesion antigen 1a.

Authors:  Alexandre Jacques; Christian Bleau; Claire Turbide; Nicole Beauchemin; Lucie Lamontagne
Journal:  Immunology       Date:  2009-08-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.